AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended). An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of stimulating angiogenesis in a tissue associated with a disease condition, wherein said packaging material comprises a label which indicates that said pharmaceutical composition is administered to a patient for treating disease conditions by stimulating angiogenesis, and wherein said pharmaceutical composition consists essentially of at least about 0.1 weight percent of a Raf protein in a physiologically tolerable excipient or carrier therefore; wherein the active Raf protein is selected from the group consisting of e-Raf of: c-Raf (SEQ ID NO: 2), a protein having the amino acid sequence eorresponding to consisting of residues 306 through 648 of SEQ ID NO: 2, and Raf-caax (SEQ ID NO: 7).

Claim 2 (cancelled).

Claim 3 (currently amended). The article of manufacture of claim 1 wherein said active Raf protein is eRaf c-Raf (SEQ ID NO: 2).

Claim 4 (cancelled).

Claim 5 (previously presented). The article of manufacture of claim 1 wherein said active Raf protein is Raf-caax (SEQ ID NO: 7).

Claim 6 (previously presented). The article of manufacture of claim 1 wherein said tissue has poor circulation.

Claims 7-13 (cancelled).

Claim 14 (currently amended). The article of manufacture of claim 1 wherein the label indicates that said pharmaceutical composition is administered to a patient by intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

Claim 15 (currently amended). The article of manufacture of claim 1 wherein the label indicates that said pharmaceutical composition is administered to a patient as a single dose intravenously.

Claims 16-67 (cancelled).